Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Motixafortide (Aphexda) Peptide
CXCR4 antagonist peptide that mobilizes stem cells for autologous transplant in multiple myeloma.
What is Motixafortide (Aphexda)?
Motixafortide (Aphexda) is a cxcr4 antagonist · hematology peptide studied for stem cell mobilization for autologous transplant in multiple myeloma. Below is an educational overview of Motixafortide (Aphexda) peptide benefits, mechanism, common research protocols, dosage references, and known side effects.
Plain-Language Label Highlights
Brand names: Aphexda
Mobilization of stem cells for autologous transplant in adults with multiple myeloma (used with G-CSF).
A single shot given with G-CSF that helps release stem cells from the bone marrow so they can be collected for a transplant.
- •Injection-site reactions (pain, redness, itching)
- •Flushing
- •Back pain
- •Nausea
- •Hypersensitivity / anaphylactoid reactions
- •Tumor-cell mobilization in leukemia
- •Embryo-fetal toxicity
- •Pregnancy
- •Known hypersensitivity to motixafortide
- •Active leukemia (caution — tumor-cell mobilization risk)
Educational summary of the FDA prescribing information. Not a substitute for the full label or medical advice. Always discuss with a licensed prescriber.
Motixafortide (Aphexda) Mechanism of Action
A long-acting synthetic peptide antagonist of the CXCR4 chemokine receptor. Disrupts the CXCR4/CXCL12 axis anchoring hematopoietic stem cells in the bone marrow, releasing them into circulation for collection. Used with G-CSF.
Motixafortide (Aphexda) Research Areas & Benefits
Motixafortide (Aphexda) Dosage & Common Research Protocols
Single SC dose given with G-CSF before apheresis.
Protocols summarized for educational reference from published research. Not dosing guidance.
Motixafortide (Aphexda) Studies & Cited Research
GENESIS phase 3 trial of motixafortide + G-CSF
Higher proportion of patients collected ≥6×10^6 CD34+ cells/kg in ≤2 apheresis sessions vs G-CSF alone.
Why we trust this source: Published in a peer-reviewed scientific journal with editorial and reviewer oversight.
Citations are linked to PubMed, Google Scholar, and Crossref searches so you can verify the source independently. All references are reviewed during our editorial passes (last reviewed June 1, 2026).
Motixafortide (Aphexda) Side Effects & Safety Considerations
- •FDA-approved September 2023.
- •Common side effects: injection-site reactions, flushing, pruritus.
- •Risk of hypersensitivity / anaphylactoid reactions.
Explore more peptides
Educational Information Only — Not Medical Advice
All content on this page is for educational and informational purposes only. It is not medical advice, diagnosis, or treatment. We make no claims that any peptide can diagnose, treat, cure, or prevent any disease. Peptides discussed are not FDA-approved for the indications listed unless explicitly stated otherwise.
Always consult a licensed healthcare provider before beginning any wellness protocol. Statements have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability, eligibility, and pricing may vary.
Ask the Library
Ask anything about peptides — answers come from our curated reference library with citations.